Angiogenesis, the formation of new blood vessels from a preexisting vascular bed , is a complex multistep process involving endothelial cell (EC) growth, migration , and microvessel morphogenesis.
These processes are controlled by positive and negative angiogenic factors which regulate one or more of these key events1). Angiogenesis plays a central role in the growth and development of normal tissues and in a variety of pathologic settings. It is an essential process in the progression of malignant tumors because solid tumors cannot grow beyond 1-2 mm diameter without angiogenesis2) .
Intratumoral microvessel density (IMVD) is a measurement of tumor angiogenesis and can be determined using antibodies against endothelial cells (ECs). It is closely correlated with tumor growth Kumar et al16~ and Tanaka et al18) demonstrated that the CD 105-IMVD is an independent prognostic factor in breast carcinoma and non-small cell lung cancer, whereas the CD34-IMVD was not. They evaluated angiogenesis using an anti-CD34 mAb and an anti-CD 105 mAb and reported that the CD 105-IMVD showed a statistical correlation with postoperative survival, whereas the CD34-IMVD did not. These results demonstrating the superiority of the CD105-IMVD over the CD34-IMVD as a prognostic factor also support the validity of CD 105-IMVD in evaluation of angiogenesis. To confirm the prognostic significance of the CD 105-IMVD, further studies need to be conducted. Another study also demonstrated that CD 105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas22) . However in the present study, we found that there were no significant differences between the IMVD (CD34-IMVD or CD 105-IMVD) and age, gender, tumor location, lymph node metastasis, distant metastasis, pT (UICC) or stage ( UICC) in 16 cases of pancreatic cancer. The results may suggest that IMVD (CD34-IMVD or 
